On April 23, 2026, Scinai Immunotherapeutics Ltd. entered into a Securities Purchase Agreement for a private placement, selling 5,208,333 ADSs at $0.48 each, raising approximately $2.61 million to support its growth strategy in immunotherapy, subject to customary closing conditions.